ClinicalTrials.govclosed
Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomi
ClinicalTrials.gov study NCT07151560. IPD Sharing: NO. Countries: 0. Publications: 0.
ShareScore
20/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4